BPC-157: Discovery and Regulatory History

Introduction

BPC-157 is a stable synthetic pentadecapeptide whose research history spans more than three decades. Its origins lie in gastrointestinal research at the University of Zagreb in the early 1990s, from which it evolved into one of the more extensively characterized research-use peptides in the preclinical literature. This article traces the compound's discovery period, the trajectory of early research, principal regulatory milestones, and the current landscape of scientific inquiry. All characterizations of research findings are based on published, peer-reviewed sources. For information on sourcing and quality verification, see the BPC-157 sourcing and quality article.

Discovery Period

The isolation and characterization of BPC-157 is attributed to a research group led by Predrag Sikirić at the University of Zagreb Medical School, Croatia, working in collaboration with researchers including M. Petek, R. Rucman, S. Seiwerth, and Z. Grabarević, among others. Their foundational 1993 publication in Journal of Physiology, Paris described a protein extracted from human gastric juice and designated it BPC — Body Protection Compound — based on the hypothesis that gastric-derived proteins mediated systemic protective responses [1]. The 15-amino acid partial sequence designated BPC-157 emerged from that characterization work as a subject of focused investigation.

The conceptual framework underlying the discovery was rooted in the idea of gastric cytoprotection, a concept that had gained scientific traction through work in the 1970s and 1980s establishing that prostaglandins and other gastric mediators could protect gastrointestinal mucosa from injury without necessarily neutralizing gastric acid. Sikirić and colleagues proposed that BPC-derived peptides represented a distinct class of endogenous gastric protective molecules. BPC-157's stability in the acidic gastric environment — an atypical property for a 15-amino acid sequence — was highlighted as functionally significant in that early work [1].

The Croatian research group's institutional context is relevant to the history of BPC-157: the University of Zagreb School of Medicine and its associated institute provided the organizational infrastructure for what became a sustained, multi-decade research program. Early funding and development activities were conducted in cooperation with the Croatian pharmaceutical company Pliva, which later sponsored the early-phase human clinical investigations.

Early Research (1993–2005)

Following the 1993 publication, the Sikirić group published a series of preclinical studies throughout the mid-1990s and early 2000s examining BPC-157 in rodent gastrointestinal injury models, including cysteamine-induced duodenal ulcer and reflux esophagitis models. A 1997 study in Pharmacology reported that BPC-157 interacted with dopaminergic and adrenergic systems in the context of gastric mucosal protection, signaling that the compound's pharmacological profile extended beyond gastrointestinal mucosal effects [2] — an observation that would define the research program's expansion into musculoskeletal, neurological, and vascular domains.

During this period, BPC-157 was also examined in models of wound healing, bone repair, and tendon injury. A 1998 safety evaluation described the compound as achieving no identified lethal dose in rodent limit-test safety assessments [3], providing the preclinical safety foundation for advancing toward human clinical investigation.

Regulatory Milestones

Early-Phase Human Studies (2000s–2010s)

Building on the preclinical safety profile established during the 1990s, the Croatian pharmaceutical company Pliva advanced BPC-157 into early-phase human clinical investigation under several program designations: PL-10, PLD-116, and PL14736. These programs focused primarily on inflammatory bowel disease, including mild to moderate ulcerative colitis, and wound healing. Published preclinical papers from the Sikirić group referenced these human investigations as having established a preliminary human safety profile for the compound [4].

The Pliva clinical program represented an important step in the compound's translational arc — the transition from animal models to human participants. Full trial reports from these investigations exist as secondary citations in the preclinical literature; the program provided the clinical foundation that subsequent investigators have referenced when characterizing BPC-157's human safety data.

Regulatory Status and Pipeline Context

As of the preparation of this article, BPC-157 has not received marketing authorization from the FDA, the EMA, or equivalent regulatory agencies for any therapeutic indication. The 2025 literature review by Józwiak and colleagues noted this status and identified advancement of clinical studies confirming health benefits in humans as the central next step in the compound's regulatory pathway [5]. BPC-157 is classified as a research-use-only (RUO) compound in the United States. The BPC-157 product page provides sourcing and verification details for research applications. A parallel regulatory-stage compound within the healing and regenerative research cluster is KPV, which has similarly not received marketing authorization for any therapeutic indication.

No publicly available Investigational New Drug (IND) application advancing BPC-157 to pivotal Phase III trials has been identified in publicly accessible regulatory databases as of the preparation of this article, and the path from the Pliva early-phase program to registration-quality trials remains an open question for the field.

WADA Monitoring Program

The World Anti-Doping Agency (WADA) included BPC-157 on its Monitoring Program list in 2022. Placement on the Monitoring Program is distinct from placement on the Prohibited List: monitored substances are subject to detection and data collection in competitive athletes, but are not prohibited under the World Anti-Doping Code. The purpose of monitoring is to identify use patterns that may later justify consideration for prohibition. As of the most recent available WADA documentation, BPC-157 remains not listed as a prohibited substance.

Current Research Landscape

Volume and Scope of Published Literature

By the mid-2020s, the peer-reviewed literature on BPC-157 encompassed several hundred publications, the majority originating from the University of Zagreb group but with significant contributions from independent research groups in Taiwan, China, South Korea, and North America. The Taiwan group led by Chang and colleagues at Chang Gung University produced a series of rigorous in vitro studies on tendon fibroblast biology beginning in the 2010s [6,7]. Investigators at the Air Force Medical University in China published pharmacokinetic characterization data in 2022, providing the first systematic assessment of the compound's pharmacokinetic profile in rat and dog models [8].

A 2025 literature and patent review in Pharmaceuticals by Józwiak and colleagues catalogued the breadth of the research corpus, identifying published investigations across gastrointestinal, musculoskeletal, neurological, vascular, hepatic, and renal domains [5]. The review also identified a growing body of patent activity in multiple jurisdictions covering synthetic formulations, delivery systems, and combination compositions — a marker of sustained commercial and translational interest in the compound.

Systematic Reviews and Evidence Assessment

The maturation of the BPC-157 literature to a size sufficient for systematic review began to occur in the early 2020s. A 2025 systematic review published in HSS Journal by Vasireddi and colleagues applied systematic review methodology to the orthopaedic and sports medicine literature on BPC-157, reviewing the totality of published animal and human studies in that domain [9]. The review described the preclinical evidence base as consistent in broad direction across tissue types, and identified well-designed human randomized controlled trials as the priority for advancing the field.

A 2025 narrative review in Current Reviews in Musculoskeletal Medicine by Lulofs and colleagues similarly characterized the compound as demonstrating "robust regenerative and cytoprotective effects in preclinical studies" and identified human clinical investigation as the next milestone [10].

Scientific Dialogue and Ongoing Investigation

The 2025 publication of the Józwiak literature review prompted an active exchange in the scientific literature. The Sikirić group published a commentary in Pharmaceuticals articulating their position on BPC-157's NO system modulation and angiogenic mechanisms [11]. Józwiak and colleagues published a reply [12], reflecting an ongoing scientific dialogue that characterizes a research field in productive development. The field is at the stage where preclinical characterization has matured to the point of informing the design of clinical investigations.

References

1. Sikirić P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87(5):313–327. PMID: 8298609. https://pubmed.ncbi.nlm.nih.gov/8298609/

2. Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, et al. Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Pharmacology. 1997;54(1):49–56. PMID: 9073154. https://pubmed.ncbi.nlm.nih.gov/9073154/

3. Sikirić P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye's stress coping response: progress, achievements, and the future. Gut. 2020 (review context). PMC7096228. https://pmc.ncbi.nlm.nih.gov/articles/PMC7096228/

4. Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. J Pharmacol Sci. 2007;104(1):7–17. PMID: 17713731. https://pubmed.ncbi.nlm.nih.gov/17713731/

5. Józwiak P, Lipiec K, Maleszka A, Krześlak A. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals. 2025;18(2):185. PMID: 40005999. DOI: 10.3390/ph18020185. https://pubmed.ncbi.nlm.nih.gov/40005999/

6. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PMID: 21030672. DOI: 10.1152/japplphysiol.00945.2010. https://pubmed.ncbi.nlm.nih.gov/21030672/

7. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–77. PMC6271067. DOI: 10.3390/molecules191119066. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/

8. He Y, Chang R, Han B, Shi C, Li Y, Wang H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1086885. PMC9794587. https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/

9. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PMID: 40756949. DOI: 10.1177/15563316251355551. https://pubmed.ncbi.nlm.nih.gov/40756949/

10. Lulofs R, Spaans M, Kokshoorn NE. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025. PMID: 40789979. https://pubmed.ncbi.nlm.nih.gov/40789979/

11. Sikirić P, Sikirić SP, Smoday IM, Krezić I, Zizek H, Sikiric S. BPC 157 therapy: targeting angiogenesis and nitric oxide's cytotoxic and damaging actions, but maintaining, promoting, or recovering their essential protective functions. Pharmaceuticals. 2025. PMC12567428. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12567428/

12. Józwiak P, Lipiec K, Maleszka A, Krześlak A. Reply to Sikirić et al.: BPC 157 therapy. Pharmaceuticals. 2025. PMC12567171. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12567171/